Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimizing and Improving Immunotherapy for Hepatocellular Carcinoma: the IO-MARC Study

NCT07623265 is registered in ClinicalTrials.gov with Universitaire Ziekenhuizen KU Leuven as lead sponsor.

NCT NCT07623265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07623265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimizing and Improving Immunotherapy for Hepatocellular Carcinoma: the IO-MARC Study
Lead sponsor
Universitaire Ziekenhuizen KU Leuven
Phase
Not applicable
Overall status
Recruiting
Start date
March 4, 2025
Completion date
January 31, 2032
Enrollment
300 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc)